Given the onset of spondyloarthritis with axial and peripheral presentation in a patient treated with adalimumab for relapsing anterior uveitis, we decided to change the therapeutic strategy by inserting an IL-17A inhibitor drug. This evidence concerns the gene IL17A and spondyloarthropathy.